DNA damage response signaling as a predictive biomarker and synergistic therapeutic target for anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer

Thorac Cancer. 2018 Aug;9(8):901-903. doi: 10.1111/1759-7714.12785. Epub 2018 Jun 22.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents, Immunological / pharmacology
  • Antineoplastic Agents, Immunological / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Clinical Trials as Topic
  • DNA Damage* / drug effects
  • Humans
  • Immunotherapy
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Signal Transduction / drug effects

Substances

  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor